

Drug	Indication (from CDF list)	Licensed for this indication (according to the European Medicines Agency) (Y/N)?	Available to patients from (CDF)	old CDF drug remaining on new CDF list 15m Y, Y/B yes but has been reviewed, Not applicable because new drug	Listed after 1/1/18	Managed Access Agreement (data collection arrangement and commercial arrangement)	Technology appraisal status None (N), Underway (U), Completed (C), Abandoned (A), ??	NICE TA number or link to incomplete TA	Date of TA publication or expected date	Date on managed access agreement	Number of redacted areas (in addition to the commercial arrangement)	Text surrounding redaction	Description of clinical uncertainty in MA - P, I, C, O, E	Detail of uncertainty	Which study is anticipated to drive decision making next time the drug is appraised? (SACT (S), Trial (T), other (O))	SACT study requested	registration of the SACT study, link or mention of a protocol?	SACT outcomes	SACT data expected	clinical trial requested/ ongoing	name	Trial on registry Y/N?	outcome of prime interest to the NICE committee	other outcomes of interest	when are data expected?	other study maintained/req used?	routine commissioning, no NICE (typically "off label")
Alecicmb	Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	Y	28/6/18	N	Y	N	C	TA536	8/8/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1= old CDF+DCA, 2=new CDF drug+DCA, 3=old awaiting NICE, 4=old not for NICE, 5=new CDF no NICE, 6=after 1/1/18 entering commissioning via NICE, 7= old, no NICE and entering commissioning, 8=old, seen by NICE, for commissioning, 9= after 1/1/18 entering routine commissioning, no NICE (typically "off label")
Arsenic trioxide	Newly diagnosed low to intermediate risk acute promyelocytic leukaemia in CHILDREN	N	4/6/18	N	Y	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Arsenic trioxide	Relapsed/refractory acute promyelocytic leukaemia in CHILDREN	N	4/6/18	N	Y	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	9
Arsenic trioxide	Newly diagnosed low to intermediate risk acute promyelocytic leukaemia in ADULTS	Y	4/6/18	N	Y	N	C	TA526	13/6/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Arsenic trioxide	Relapsed/refractory acute promyelocytic leukaemia in ADULTS	Y	4/6/18	N	Y	N	C	TA526	13/6/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Bendamustine	Relapsed low grade lymphoma	possibly	29/7/16	Y	N	- but entering r	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Bendamustine	Relapsed multiple myeloma	possibly	29/7/16	Y	N	- but entering r	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Bevacizumab	Third line for low grade gliomas of childhood	N	29/7/16	Y	N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Bevacizumab	First line for recurrent or metastatic cervical cancer in combination with chemotherapy	Y	29/7/16	Y	N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Bevacizumab	First line for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer	Y	29/7/16	Y	N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Bortezomib	Bortezomib naive relapsed multiple myeloma	Y	29/7/16	Y	N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Bortezomib	Bortezomib-naive relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multiagent chemotherapy is not a treatment option in CHLD patient	?	29/7/16	YB	N	- but entering r	N	NA	NA	28/4/17	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	7
Brentuximab	Brentuximab-naive relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multiagent chemotherapy is not a treatment option in ADULT patients	?	29/7/16	YB	N	- but entering r	N	TA524	28/6/17	28/4/17	0	NA	O	the proportion of S	Y	retrospective ana stem cell transpl	Nov 2017	Y	supported by the ?	?	?	?	Nov 2017	Comparison in S	8		
Cabozantinib	Treatment-naïve intermediate or poor risk advanced renal cell carcinoma	Y	24/8/18	N	Y	N	C	TA463	9/8/17	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	8
Cabozantinib	First line for medullary thyroid cancer	Y	29/7/16	YB	N	N	A	TA516	March 28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	8
Clofarabine	Relapsed/refractory acute myeloblastic leukaemia	N	29/7/16	Y	N	N	N	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Clofarabine	Relapsed/refractory acute lymphoblastic leukaemia	Y	29/7/16	YB	N	N	A	https://www.nice	1/12/16	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Clofarabine	As part of 1st line therapy for high risk neuroblastoma in patients aged 12 months and above and who have both responded to induction chemotherapy and been treated with myeloablative therapy and stem cell transplantation	Y	22/8/18	N	Y	N	C	TA538	22/8/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Dihydroxymeth	RELAPSED OR REFRACTORY neuroblastoma in patients aged 12 months and above and who have both responded to intensive induction chemotherapy used to treat high risk 1st line patients and been treated with myeloablative therapy and stem cell transplantation	Y	22/8/18	N	Y	N	C	TA538	22/8/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Inotuzumab oxi	Treatment of relapsed/refractory Philadelphia positive and negative B cell precursor acute lymphoblastic leukaemia in CHLD patients	N	9/8/18	N	Y	N	U	possible GID-TA 719/8/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	9
Inotuzumab oxi	Relapsed/refractory Philadelphia positive and Philadelphia negative B cell precursor acute lymphoblastic leukaemia in ADULT patients	Y	9/8/18	N	Y	N	U	GID-TA10091	19/9/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Lenvatinib	Differentiated thyroid cancer after radioactive iodine	Y	15/2/18	N	Y	N	C	TA535	8/8/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Lenvatinib	Unresectable or metastatic, progressive, well differentiated and somatostatin receptor positive gastroenteropancreatic	Y	20/7/18	N	Y	N	C	TA539	29/8/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Midostaurin	FLT3 mutation positive acute myeloid leukaemia in adults	Y	4/6/18	N	Y	N	C	TA523	13/6/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
Nelarabine	Refractory T-cell acute lymphoblastic leukaemia or refractory T-cell lymphoblastic non-Hodgkin's lymphoma	N	29/7/16	YB	N	N	A	https://www.nice	27/12/17	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	4
Oestratamab	In combination with doxorubicin for the treatment of advanced soft tissue sarcoma in PAEDIATRIC patients	N	9/6/17	N	N	N	?	?	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	5
Palbocicb	Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	Y	16/11/17	N	N	N	C	TA495	20/12/17	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	?	?	?	?	?	?	8
Pegylated Lipos	Sarcoma (seems to be for those with cardiac problems)	N	29/7/16	Y	N	N	N	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	4
Pembrolizumab	Relapsed or refractory classical Hodgkin lymphoma in CHILDREN who are stem cell transplant-ineligible and have failed brentuximab vedotin	N	25/7/18	N	Y	N	?	?	?	?	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	9
Perfluzumab	First line treatment of locally advanced or metastatic breast cancer	HER2 only	29/7/16	Y	N	N	N	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	8
Sorafenib	Differentiated thyroid cancer after radioactive iodine	Y	29/7/16	YB	N	N	N	TA535	8/8/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	8
Vandetanib	First line treatment of medullary thyroid cancer	Y	29/7/16	YB	N	N	U	https://www.nice	19/12/18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3
Atezolizumab	Locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin based chemotherapy	Y	1/11/17	N	N	Y	C	TA492	6/12/18	12/7/18	3	in the trial proto C, O, E	OS and PFS con T	Y	N	OS, duration of t	Dec 2020	Y	IMvigor 130	Y	OS, PFS, treatm	NA	Dec 2020	NA	2		
Crizotinib	1st or subsequent line systemic therapy for ROS1-positive inoperable locally advanced/metastatic non squamous non-small cell lung cancer	Y	31/6/18	N	Y	Y	C	TA529	4/7/18	July 2018	2	dates when trials C, O	Lack of compar S	Y	Y	Treatment durati 2023 (driven by e baseline charact data	?	NA	PROFILE 1001 (Y	OS	Objective respon	April 2023	Clinical trial OxC Asian patients in	2			
Daratumumab	Relapsed and refractory multiple myeloma	Y	17/1/18	N	Y	Y	C	TA510	14/3/18	March 2018	0	NA	O	Os in a UK popul S	Y	N	Pre-progression 01/11/2019-20	Y	Phase 2 registrati Y - https://clinical	OS	longer term survi	Aug 2018	isease-specific W	2			
Ibrutinib	Waldenström's Macroglobulinaemia	Y	18/9/17	N	N	Y	C	TA461	22/11/17	sept 17	0	NA	O	magnitude of the T	Y	N	OS, Duration of t	Dec 19	Y	Phase III TOUR, I	progression-free OS and OS in pa	Dec 2019	Data from UK NA	2			
Ixabromb (with	Maintenance for relapsed, platinum-sensitive and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based SECOND line chemotherapy and who HAVE a germline BRCA mutation	Y	1/6/18	N	N	Y	C	TA523	4/7/18	NA	0	NA	O	mature OS data, T	Y	N	overall survival, e as trial	Y	pivotal ENGOT-CY	Mature OS	PFS, QOL, time i	June 2020	NA	2			

